Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden,
Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
J Innate Immun. 2021;13(3):131-147. doi: 10.1159/000513582. Epub 2021 Feb 12.
Mast cells (MCs) are versatile effector cells of the immune system, characterized by a large content of secretory granules containing a variety of inflammatory mediators. They are implicated in the host protection toward various external insults, but are mostly well known for their detrimental impact on a variety of pathological conditions, including allergic disorders such as asthma and a range of additional disease settings. Based on this, there is currently a large demand for therapeutic regimens that can dampen the detrimental impact of MCs in these respective pathological conditions. This can be accomplished by several strategies, including targeting of individual mediators released by MCs, blockade of receptors for MC-released compounds, inhibition of MC activation, limiting mast cell growth or by inducing mast cell apoptosis. Here, we review the currently available and emerging regimens to interfere with harmful mast cell activities in asthma and other pathological settings and discuss the advantages and limitations of such strategies.
肥大细胞(MCs)是免疫系统的多功能效应细胞,其特征是含有大量分泌颗粒,其中包含各种炎症介质。它们参与宿主对各种外部刺激的保护,但最广为人知的是它们对各种病理状况的有害影响,包括过敏疾病,如哮喘和一系列其他疾病。基于此,目前迫切需要能够减轻 MC 在这些相应病理状况中有害影响的治疗方案。这可以通过几种策略来实现,包括针对 MC 释放的单个介质的靶向治疗、阻断 MC 释放化合物的受体、抑制 MC 激活、限制肥大细胞生长或诱导肥大细胞凋亡。在这里,我们综述了目前可用于干预哮喘和其他病理状况中有害肥大细胞活性的方案,并讨论了这些策略的优缺点。